P21
Also known as: P021
Molecular Identifiers
Overview
Peptide derived from CNTF (ciliary neurotrophic factor). Promotes BDNF upregulation and hippocampal neurogenesis. Inhibits tau protein phosphorylation, being researched in Alzheimer's and cognitive decline models.
Modified peptide — derived from CNTF with prenylated group, non-conventional sequence
Half-life
~4-8 hours
Administration Route
Subcutaneous
Category
Cognitive & Neuroprotective
Mechanism of Action
- BDNF upregulation (brain-derived neurotrophic factor)
- Promotion of hippocampal neurogenesis
- Inhibition of tau protein phosphorylation
- Improvement of synaptic plasticity and memory
- Neuroprotective action against neurodegeneration
Dosage Protocol
Data compiled from the literature. This does not constitute medical advice.
| Parameter | Value |
|---|---|
| Dose | 5-10 mg per day via subcutaneous |
| Frequency | Once daily |
| Timing | Morning or early afternoon |
| Duration | 4-12 weeks |
Reported Side Effects
Adverse effects described in the literature. Severity and frequency vary between individuals.
- Mild headache
- Injection site pain
Product Properties
| Purity | >98% |
| Appearance | White lyophilized powder |
| Solubility | Soluble in water and bacteriostatic water |
| Source | Solid-phase peptide synthesis (SPPS) |
| Storage | Lyophilized: -20°C for up to 2 years, 2-8°C for up to 6 months. Reconstituted: 2-8°C for up to 4 weeks. Protect from light and moisture. Avoid repeated freeze-thaw cycles. |
Presentations & Preparation
Vials of P21 found in the research market:
Reconstitution
- Diluent: Bacteriostatic water
- Volume: 2 ml per vial
- Inject the diluent slowly against the vial wall
- Gently swirl until fully dissolved
- Never shake
Storage
- Lyophilized: Refrigerated 2-8°C
- Reconstituted: Refrigerated 2-8°C (up to 30 days)
- Protect from direct light
- Do not freeze after reconstitution
Scientific Studies
Published studies on P21.
Neurotrophic Peptides Incorporating Adamantane Improve Learning and Memory, Promote Neurogenesis and Synaptic Plasticity in Mice
Li B, Wanka L, Blanchard J, Liu F, Chohan MO, Iqbal K, Grundke-Iqbal I
Disease Modifying Effect of Chronic Oral Treatment with a Neurotrophic Peptidergic Compound in a Triple Transgenic Mouse Model of Alzheimer's Disease
Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Iqbal IG, Iqbal K
Related Peptides
Adamax
100-500 mcg via intranasal or subcutaneous · 1-2 times daily
Cerebrolysin
5-30 ml per injection · Once daily
Cortagen
5-10 mg per day via subcutaneous injection · Once daily
Dihexa
10-20 mg per subcutaneous injection or oral (research) · Once daily
DSIP
100-300 mcg per subcutaneous injection · Once daily
Epithalon
5-10 mg per injection · Once daily or every other day